

ANTIBODY MEDIATED REJECTION IN KIDNEY TRANSPLANTATION PUBLIC WORKSHOP—April 12 and 13, 2017

Speakers and Panelists

Renata Albrecht, MD

Director, Division of Ophthalmology and Transplant Products (DTOP)
Office of Antimicrobial Products (OAP)
Center for Drug Evaluation and Research (CDER), FDA, Silver Spring, MD

Rita Alloway, PharmD

Research Professor of Medicine
Director, Transplant Clinical Research
University of Cincinnati, Cincinnati, OH

Shukal Bala, PhD

Microbiologist, Division of Anti-Infective Products
CDER, FDA, Silver Spring, MD

Ozlem Belen MD, MPH

Deputy Director for Safety, DTOP
CDER, FDA, Silver Spring, MD

Marc Cavaillé-Coll, MD, PhD

Medical Officer, DTOP
CDER, FDA, Silver Spring, MD,

Lakhmir Chawla MD

Professor of Medicine
Veterans Affairs Medical Center, Washington D.C.

Anita S. Chong, PhD

Professor of Surgery, Department of Surgery
University of Chicago, Chicago, IL

Robert B. Colvin, MD

Benjamin Castleman Distinguished Professor of Pathology
Massachusetts General Hospital
Harvard Medical School, Boston, MA

Edward Cox, MD, MPH

Director, Office of Antimicrobial Products
CDER, FDA, Silver Spring, MD

Arjang Djamali, MD

Professor of Medicine and Surgery
Head, Nephrology Division
UW School of Medicine and Public Health, Madison, WI

Dawn Edwards

Patient Representative/Speaker

Robert S. Gaston, MD

Director, Comprehensive Transplant Institute
Robert G. Luke Endowed Chair in Transplant Nephrology
University of Alabama at Birmingham, Birmingham, AL

Howard M. Gebel, PhD

Professor, Department of Pathology
Emory University Hospital, Atlanta, GA

Mark Haas, MD, PhD

Professor of Pathology
Senior Attending Pathologist
Cedars-Sinai Medical Center, Los Angeles, CA

William Irish, PhD

Vice President-Outcomes Research and Biostatistics
CTI Clinical Trial and Consulting Services, Raleigh NC

Stuart J. Knechtle, MD

Mary and Deryl Hart Professor of Surgery
Executive Director, Duke Transplant Center
Duke University School of Medicine, Durham, NC

Gregory Knoll, MD, MSc

Professor of Medicine, Division of Nephrology
University of Ottawa, Ottawa, Ontario, Canada

Jack Lennon

Patient Representative/Speaker

Roslyn B. Mannon, MD

Professor of Medicine, Division of Nephrology
Professor of Surgery, Division of Transplantation
Director of Research, Comprehensive Transplant Institute
University of Alabama at Birmingham, Birmingham, AL

Arthur Matas, MD

Professor, Department of Surgery
Director, Renal Transplant Program
University of Minnesota, Minneapolis, Minnesota

Michael Mittelman

Patient Representative/Speaker

Robert A. Montgomery, MD, DPhil

Professor of Surgery
Director, NYU Langone Transplant Institute
New York, New York

Peter Nickerson, MD

Distinguished Professor, Internal Medicine and Nephrology
Flynn Family Chair in Renal Transplantation
University of Manitoba, Winnipeg, Manitoba

Anat Roitberg-Tambur, DMD, PhD

Director, Transplant Immunology Laboratory
Comprehensive Transplant Center
Research Professor
Feinberg School of Medicine, Northwestern University
Chicago, IL

Milagros Samaniego-Picota, MD

Professor, Internal Medicine
Medical Director, Kidney and Kidney Pancreas Transplantation
University of Michigan, Ann Arbor, MI

Mark D. Stegall, MD

General Surgeon
Mayo Clinic, Rochester, MN

Ergun Velidedeoglu, MD

Medical Officer, DTOP
CDER, FDA, Silver Spring, MD

Yan Wang, PhD

Team Lead, Statistics, Office of Biostatistics, Division of Biometrics IV
CDER, FDA, Silver Spring, MD

Chris Wiebe, MD

Assistant Professor of Internal Medicine
University of Manitoba, Winnipeg, Canada

E. Steve Woodle, MD

Professor, Chief-Division of Transplant Surgery
University of Cincinnati, Cincinnati, OH

Disclosures

Dr. Alloway receives grant support from Novartis, Onyx, GSK, Prolong, Bristol-Myers Squibb, Genzyme, and Sanofi. She serves on an advisory board for Genzyme, Sanofi, and speaker's bureau for Genzyme, Sanofi and Veloxis.

Dr. Chawla provides consultation for Nxstage Medical, Astute Medical, and Baxter Medical, and is on Sabbatical from La Jolla Pharmaceutical.

Dr. Colvin is a consultant to Shire Pharmaceuticals and Alexion Pharmaceuticals.

Dr. Djamali has received research funding from BMS (Investigator Initiated Trial), Takeda Millennium (Investigator Initiated Trial) and NIDDK (R01).

Dr. Gaston has served as a consultant during the past 12 months for CTI Clinical Trials, Immucor, Novartis and Veloxis.

Dr. Mark Haas serves as a paid consultant to Shire ViroPharma and AstraZeneca.

Dr. William Irish is a full time employee of CTI Clinical Trial and Consulting Services.

Dr. Knoll has received research grant support from Astellas Canada and the Canadian Institutes of Health Research.

Dr. Mannon has received grant support from Alexion, Astellas, Quark Pharmaceuticals and Care Dx (in addition to Honorarium with CareDx).

Dr. Matas serves as a PI and receives grant support from National Institute of Health, Astellas, Novartis, Bristol-Myers Squibb, and Sanofi. In the last year Dr. Matas participated in advisory board meetings to Astellas, Novartis and Veloxis and received an honorarium. Dr. Matas had a talk sponsored by Sanofi and received an honorarium and travel expenses.

Dr. Nickerson serves as a consultant for Astellas, GSK, Novartis and Vitaeris.

Dr Roitberg-Tambur is a consultant to Astellas and directs the core lab for the Astound clinical trial, Dr Roitberg-Tambur is also a consultant to CSL Behring and has received consultation fees.

Dr. Stegall has served on the Ad Board for Novartis, Roche, and Astellas. Dr. Stegall also received a Mayo Contract—Transplant Genomics, Inc.

Dr. Woodle has served as a consultant, speaker and received research grants from Sanofi; received research grants from Bristol Myers Squibb; research grants from Amgen and research grants from Glaxo Smith Kline.